solarseven/iStock via Getty Images
Cyclocel Pharmaceuticals (NASDAQ:CYCC) said Friday that it entered into a securities purchase agreement with investor David Lazar, under which it agreed to purchase 1 million Series C convertible preferred shares and 2.1 million shares from the company.